Exelixis, Inc.
$46.05
$0.80(-1.71%)
Exelixis, Inc.
EXEL
$46.05
$0.80(-1.71%)
Exelixis, Inc.
EXEL
NASDAQ
$46.05
$0.80(-1.71%)
Chart
Upcoming Earnings
Next report date
May 5, 2026
Report period
Q2 2026
EPS Estimate
$0.76
Revenue Estimate
$605.01M
Key stats
52-Week Range$46.05
$33.76
$49.62
Market capitalization
$11.67BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
16.28Basic EPS (TTM)
$2.88Net income (TTM)
$782.57MRevenue (TTM)
$2.32BAvg. volume
2.78MBeta (1Y)
0.42Employees
1.15KMarket capitalization
$11.67BDividend yield (indicated)
0.00%Price to earnings Ratio (TTM)
16.28Basic EPS (TTM)
$2.88Net income (TTM)
$782.57MRevenue (TTM)
$2.32BAvg. volume
2.78MBeta (1Y)
0.42Employees
1.15KScreener Quick Check
Sign in to check this stock against your screeners
Sign InAbout Exelixis, Inc.
Sector
Healthcare
Industry
Biotechnology
CEO
Michael Morrissey
Website
www.exelixis.comHeadquarters
1851 Harbor Bay Parkway, Alameda, CA, 94502
IPO Date
2000-04-17
Identifiers
ISIN
US30161Q1040Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines...
Related Stocks
$135.30
1D:
0.6%
1Y:
250.7%
US76155X1000Healthcare
Mkt Cap
$28.24B
P/E Ratio TTM
-23.8
Revenue TTM
$0.00
Beta
1.01
Earnings TTM
$-1.13B
Dividend Yield TTM
0.00%
$50.73
1D:
-4.0%
1Y:
85.2%
US60770K1079Healthcare
Mkt Cap
$20.12B
P/E Ratio TTM
-7.6
Revenue TTM
$1.94B
Beta
1.34
Earnings TTM
$-2.82B
Dividend Yield TTM
0.00%
Dividend Overview
This company does not pay dividends
Financials
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate
Performance
Margin trends
Debt level and coverage
Earnings
Next: Q2 '26
Actual
Estimate